Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants

SIMPLE SUMMARY: In our study, we retrospectively collected data of patients with germline CDKN2A pathogenic variants who received targeted therapy for advanced melanoma across four European centers. Since loss of CDKN2A function may intrinsically limit the activity of MAPK-directed targeted therapy,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Spagnolo, Francesco, Dalmasso, Bruna, Tanda, Enrica, Potrony, Miriam, Puig, Susana, van Doorn, Remco, Kapiteijn, Ellen, Queirolo, Paola, Helgadottir, Hildur, Ghiorzo, Paola
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8157545/
https://ncbi.nlm.nih.gov/pubmed/34069952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102440
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados